NuCana plc
NCNAHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeNuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer in the United States. At a $5.8M market cap, NuCana plc ranks as a micro-cap company within healthcare. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines.
Market Cap
$5.8M
Beta
2.24
P/E (TTM)
0.02
P/E (Fwd)
-0.15
EPS (TTM)
$67.41
EPS (Fwd)
$-9.43
ROE
-70.3%
ROA
-43.5%
Cash
$19.5M
Total Debt
$672,000
Free CF
-$6.4M
52W Change
-51.6%
Annual Financials
Cash vs Debt
Where NCNA stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, NCNA finished 23.63% below its 150-day moving average ($1.82) and 38.50% below its 200-day moving average ($2.26). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NCNA overbought or oversold?
At the September 3, 2026 close, NCNA's RSI(14) was 45.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
NuCana plc holds $19.5M in cash against $672K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. Free cash flow is running at -$6.4M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -70.3% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
A beta of 2.24 means NCNA is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing NCNA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.